|本期目录/Table of Contents|

[1]陈华萍,陈晓龙,胡明冬.难治性哮喘的发病机制及诊治进展[J].中华肺部疾病杂志,2024,(01):144-147.[doi:10.3877/cma.j.issn.1674-6902.2024.01.032]
点击复制

难治性哮喘的发病机制及诊治进展(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2024年01期
页码:
144-147
栏目:
综述
出版日期:
2024-02-20

文章信息/Info

Title:
-
作者:
陈华萍; 陈晓龙; 胡明冬
400037 重庆,陆军(第三)军医大学第二附属医院老年医学与特勤医学科
Author(s):
-
关键词:
支气管哮喘;  发病机制;  诊治进展
Keywords:
-
分类号:
R562
DOI:
10.3877/cma.j.issn.1674-6902.2024.01.032
摘要:
-
Abstract:
-

参考文献/References:

1 Pihnastyi OM, Kozhyna OS. Use of the complex of models of regression for analysis of the factors that determine the severity of bronchial asthma[J]. Intern Med J, 2020, 2(2): 107-118.
2 Milena D, Tatjana JS, Ivana S, et al. Genetic variants of vitamin D receptor and antioxidant enzyme genes in bronchial asthma:epistatic interactions[J]. Ann Allergy Asthma Immunol, 2020, 125(6): 701-703.
3 Elsaid A, Shoaib RMS, Badr SS, et al. Polymorphisms of interleukin 4 and interleukin 4 receptor genes and bronchial asthma risk among Egyptian children[J]. Clin Biochem, 2021, 93(1): 66-72.
4 Singh S. Bronchial challenge test in patients with a history suggestive of bronchial asthma with normal spirometric studies[J]. Med J Armed Forces India, 2020, 77(1): 82-85.
5 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识(2021版)[J]. 中华结核和呼吸杂志, 2022, 45(4): 341-354.
6 Qingling Zhang, Xiuhua Fu, Changzheng Wang, et al. Severe eosinophilic asthma in Chinese C-BIOPRED asthma cohort[J]. Clin Transl Med, 2022, 12(2): e710.
7 王文雅. 深入了解中外重度哮喘疾病负担和人群特征[J]. 中华医学杂志, 2020, 100(14): 1106-1111.
8 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023, http://www.ginaasthma.org/.
9 Deckers J, De Bosscher K, Lambrecht BN, et al. Interplay between barrier epithelial cells and dendritic cells in allergic sensitization through the lung and the skin[J]. Immunol Rev, 2017, 278(1): 131-144.
10 Akar-hibril N, sale T, stovic A, et al. Allergic endotypes and phenotypes of asthma[J]. J Allergy Clin Immunol Pract, 2020, 8(2): 429-440.
11 Bacharier LB, Jackson DJ. Biologics in the treatment of asthma innchildren and adolescents[J]. J Allergy Clin Immunol, 2023, 151(3): 581-589.
12 Varricchi G, Poto R, Marone G, et al. IL-3 in the development and function of basophils[J]. Semin Immunol, 2021, 54: 101510.
13 Walsh GM. Recent developments in the use of biologics targeting IL-5, IL-4 or IL-13 in severe refractory asthma[J]. Expert Rev Respir Med, 2018, 12(11): 957-963.
14 Fu Y, Wang J, Zhou B, et al. An IL-9 pulmonary macrophage axis defines the allergic lung inflammatory environment[J]. Sci Immunol, 2022, 7(68): eabi9768.
15 Nabe T. Steroid-resistant asthma and neutrophils[J]. Biol Pharm Bull, 2020, 43(1): 31-35.
16 Kawayama T, Kinoshita T, Matsunaga K, et al. Role of regulatory T cells in airway inflammation in asthma[J]. Kurume Med J, 2018, 64(3): 45-55.
17 Limkar AR, Percopo CM, Redes JL, et al. Persistent airway hyperre-sponsiveness following recovery from infection with pneumonia virus of mice[J]. Viruses, 2021, 13(5): 728.
18 Mavissakalian M, Brady S. The current state of biologic therapies for treatment of refractory asthma[J]. Clin Rev Allergy Immunol, 2020, 59(2): 195-207.
19 Fang L, Sun Q, Roth M. Immunologic and non-immunologic mechanisms leading to airway remodeling in asthma[J]. Int J Mol Sci, 2020, 21(3): 757.
20 Boulet LP. Airway remodeling in asthma:update on mechanisms and therapeutic approaches[J]. Curr Opin Pulm Med, 2018, 24(1): 56-62.
21 Pavón-Romero GF, Serrano-Pérez NH, García-Sánchez L, et al. Neuroimmune pathophysiology in asthma[J]. Front Cell Dev Biol, 2021, 9: 663535.
22 Sui P, Wiesner DL, Xu J, et al. Pulmonary neuroendocrine cells amplify allergic asthma responses[J]. Science, 2018, 360(6393): eaan8546.
23 Niimi A, Fukumitsu K, Takeda N, et al. Interfering with airwaynerves in cough associated with asthma[J]. Pulm Pharmacol Ther, 2019, 59: 101854.
24 赵茜叶, 赵德育. 儿童难治性哮喘的识别与处理[J]. 中华实用儿科临床杂志, 2018, 33(16): 1204-1207.
25 中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2020年版)[J]. 中华结核和呼吸杂志, 2020, 43(12): 1023-1048.
26 谢文峰, 郑东升. 长效β受体激动剂联合吸入性糖皮质激素治疗重症哮喘的临床分析[J]. 中国社区医师, 2019, 35(21): 57,59.
27 黄凤玲. 个体化健康教育对小儿哮喘治疗依从性及哮喘控制率的影响[J]. 临床合理用药杂志, 2017, 10(11): 147-148.
28 张 路, 陈丽霞. 重症哮喘患者糖皮质激素反应性及其机制的研究进展[J]. 医学综述, 2017, 23(19): 3801-3805, 3811.
29 崔鑫洋. 茶碱类药物在支气管哮喘治疗中的合理应用[J]. 中国医药指南, 2021, 19(20): 38-39.
30 莫丽慧, 钟丽花. 孟鲁司特联合布地奈德治疗支气管哮喘患儿的临床观察[J]. 中国药房, 2017, 28(14): 1981-1984.
31 金 明, 朱海玲, 李任翔, 等. 抗白三烯治疗对重症哮喘患者肺功能和炎症细胞因子水平的影响[J/CD]. 中华肺部疾病杂志(电子版), 2018, 11(2): 214-216.
32 Trischler J, Bottoli I, Janocha R, et al. Ligelizumab treatment for severe asthma: learnings from the clinical development programme[J]. Clin Transl Immunology, 2021, 10(3): e1255.
33 李春晓, 张 敏, 熊庄莉, 等. 瑞利珠单抗治疗严重哮喘的研究现状[J]. 中国临床药理学杂志, 2018, 34(8): 996-999.
34 Del GS, Eiwegger T, Firinu D, et al. Efficacy and safety of treatment with biologicals(benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab)for severe eosinophilic asthma. A systematic review for the EAACI guidelines-recommendations on the use of biologicals in severe asthma[J]. Allergy, 2020, 75(5): 1023-1042.
35 孙 莹, 蔡莉莉, 李 璇, 等. 贝那利珠单抗治疗重度嗜酸粒细胞性哮喘的临床研究进展[J]. 实用药物与临床, 2023, 26(5): 461-466.
36 Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma[J]. New England Journal of Medicine, 2018, 378(26): 2486-2496.
37 Liu Y, Zhang S, Chen R, et al. Meta-analysis of randomized controlled trials for the efficacy and safety of antiinter leukin-13 therapy with lebrikizumab in patients with uncontrolled asthma[J]. Allergy AsthmaProc, 2018, 39(5): 332-337.
38 Corren J, Karpefors M, Hellqvist S, et al.Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: A post hoc analysis of the PATHWAY phase 2b study[J]. J Asthma Allergy, 2021, 14(11): 1-11.
39 Epstein TEG, Calabria CW. Is immunotherapy safe for treatment of severe asthma[J]. Curr Opin Allergy Clin Immunol, 2022, 22(6): 396-401.
40 Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study[J]. Lancet, 2019, 394(10196): 407-418.
41 王东辉, 张 方. 重症支气管哮喘的诊治进展[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(5): 638-641.
42 Chaudhuri R, Rubin A, Sumino K, et al. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma(BT10+): a follow-up of three randomised controlled trials[J]. Lancet Respir Med, 2021, 9(5): 457-466.

备注/Memo

备注/Memo:
基金项目: 国家重点研发计划(2020YFC2008900, 2020YFC2008903)
陆军军医大学科技创新能力提升专项项目(青年培育项目)(2022XQN33)
通信作者:胡明冬, Email: humingdong@ tmmu.edu.cn
陈晓龙, Email: 1094876455@qq.com
更新日期/Last Update: 2024-02-20